Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

53.62 -3.10 (-5.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,250,096
Open 56.04
Bid (Size) 52.00 (1)
Ask (Size) 53.61 (1)
Prev. Close 56.72
Today's Range 52.37 - 56.17
52wk Range 41.50 - 90.32
Shares Outstanding 8,168,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+17.3%
+17.3%
1 Month
-25.1%
-25.1%
3 Month
-31.4%
-31.4%
6 Month
+8.0%
+8.0%
1 Year
+1.6%
+1.6%

More News

Read More
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
From Gibbs Mura
Via Business Wire
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
Via Stocktwits
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside
Via Stocktwits
Topics Death
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
Via Benzinga
Soleno Therapeutics's Earnings: A Preview
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fortinet, Roblox, Soleno, and Simulations Plus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
Via Benzinga
Soleno (SLNO) Q2 Revenue Jumps 30%
Via The Motley Fool
Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance
Via Chartmill
Topics Earnings
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Via Investor's Business Daily
Topics Intellectual Property
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress
Via Benzinga
Topics Initial Public Offering

Frequently Asked Questions

Is Soleno Therapeutics, Inc. - Common Stock publicly traded?
Yes, Soleno Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Soleno Therapeutics, Inc. - Common Stock trade on?
Soleno Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soleno Therapeutics, Inc. - Common Stock?
The ticker symbol for Soleno Therapeutics, Inc. - Common Stock is SLNO on the Nasdaq Stock Market
What is the current price of Soleno Therapeutics, Inc. - Common Stock?
The current price of Soleno Therapeutics, Inc. - Common Stock is 53.62
When was Soleno Therapeutics, Inc. - Common Stock last traded?
The last trade of Soleno Therapeutics, Inc. - Common Stock was at 09/12/25 04:00 PM ET
What is the market capitalization of Soleno Therapeutics, Inc. - Common Stock?
The market capitalization of Soleno Therapeutics, Inc. - Common Stock is 438.01M
How many shares of Soleno Therapeutics, Inc. - Common Stock are outstanding?
Soleno Therapeutics, Inc. - Common Stock has 438M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.